

Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/V0A0C93D34DEN.html>

Date: April 2021

Pages: 54

Price: US\$ 125.00 (Single User License)

ID: V0A0C93D34DEN

Abstracts

Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Valneva SE (Valneva) is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, Zika virus, and infections caused by *Clostridium difficile*. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia-Pacific, Europe, and the Middle East. It operates in Austria, Sweden, the UK, France, the US, and Canada. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Apr 07,2021: Valneva's Covid-19 vaccine shows robust immune response in trial

Mar 24,2021: Valneva Publishes its FY 2020 Audited Consolidated Financial Statements

Mar 13,2021: Valneva Announces Supervisory Board Changes

Feb 25,2021: Valneva reports FY 2020 results and major corporate achievements

Jan 15,2021: Valneva announces amendment to Deerfield and OrbiMed debt facility

terms

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Valneva SE - Key Facts
Valneva SE - Key Employees
Valneva SE - Key Employee Biographies
Valneva SE - Major Products and Services
Valneva SE - History
Valneva SE - Company Statement
Valneva SE - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Valneva SE - Business Description
Product Category: Dukoral
Overview
Performance
Key Stats
Product Category: Ixiaro/Jespect
Overview
Performance
Key Stats
Product Category: Lyme VLA15
Performance
Product Category: Other
Performance
Product Category: Third Party Products
Performance
Geographical Segment: Austria
Performance
Geographical Segment: Canada
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Nordics

Performance

Geographical Segment: Other Europe

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: United Kingdom

Performance

Geographical Segment: United States

Performance

Valneva SE - Corporate Strategy

Valneva SE - SWOT Analysis

SWOT Analysis - Overview

Valneva SE - Strengths

Valneva SE - Weaknesses

Valneva SE - Opportunities

Valneva SE - Threats

Valneva SE - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Valneva SE, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Apr 07, 2021: Valneva's Covid-19 vaccine shows robust immune response in trial

Mar 24, 2021: Valneva Publishes its FY 2020 Audited Consolidated Financial Statements

Mar 13, 2021: Valneva Announces Supervisory Board Changes

Feb 25, 2021: Valneva reports FY 2020 results and major corporate achievements

Jan 15, 2021: Valneva announces amendment to Deerfield and OrbiMed debt facility terms

Jan 11, 2021: Valneva strengthens management team; appoints Perry Celentano as interim COO and David Lawrence as acting CFO

Jan 07, 2021: Valneva reports FY 2020 cash of over €200 million

Nov 03, 2020: Valneva reports nine month results marked by further major corporate achievements

Sep 18, 2020: Valneva announces retirement of chief financial officer David Lawrence

Aug 06, 2020: Valneva announces appointment of Juan Carlos Jaramillo as Chief Medical Officer

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Valneva SE, Key Facts
Valneva SE, Key Employees
Valneva SE, Key Employee Biographies
Valneva SE, Major Products and Services
Valneva SE, History
Valneva SE, Subsidiaries
Valneva SE, Key Competitors
Valneva SE, Ratios based on current share price
Valneva SE, Annual Ratios
Valneva SE, Annual Ratios (Cont...1)
Valneva SE, Annual Ratios (Cont...2)
Valneva SE, Interim Ratios
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Valneva SE, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Valneva SE, Performance Chart (2016 - 2020)

Valneva SE, Ratio Charts

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/V0A0C93D34DEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V0A0C93D34DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970